Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.35 |
| ▸ | LGMN | Q99538 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.34 |
| ▸ | PTGES | O14684 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2834950 | 0.93 | S1PR3 (0.40) | CYP3A4DYRK1ACYP11B2S1PR3LGMN | |
| SCHEMBL2833981 | 0.92 | CYP3A4 (0.40) | CYP3A4DYRK1AS1PR3LGMNAAK1 | |
| SCHEMBL2833102 | 0.86 | KDM4D (0.42) | CYP11B2S1PR3ALDH1A1 | |
| SCHEMBL2834200 | 0.85 | EIF2S1 (0.38) | CYP3A4DYRK1ACYP11B2S1PR3AAK1 | |
| SCHEMBL2832196 | 0.83 | CYP11B2 (0.41) | CYP3A4DYRK1ACYP11B2AAK1 | |
| SCHEMBL2839734 | 0.81 | S1PR3 (0.36) | CYP3A4DYRK1AS1PR3AAK1 | |
| SCHEMBL2833210 | 0.80 | AKR1C3 (0.41) | CYP11B2S1PR3AAK1 | |
| SCHEMBL2833402 | 0.80 | MEN1 (0.36) | S1PR3AAK1ALDH1A1 | |
| SCHEMBL2843147 | 0.80 | AKR1C3 (0.41) | DYRK1AS1PR3AAK1 | |
| SCHEMBL2841558 | 0.79 | S1PR3 (0.38) | CYP3A4DYRK1ACYP11B2S1PR3LGMN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367838-B2 | Amines or amino alcohols as GLYT1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120232033-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | KOLCZEWSKI SABINE (DE) | 2012-09-13 | — | — | US | disclosed |
| EP-2398558-A1 | AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-12-28 | — | — | EP | disclosed |
| WO-2010094659-A1 | AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-26 | — | — | WO | disclosed |
| US-20100210592-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | HOFFMANN-LA ROCHE, INC. | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232033-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | GFPT1, CEPT1, SLC18A2 | CYP3A4 1043/4885DYRK1A 2693/4885CYP11B2 1430/4885 |
| US-20100210592-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | GFPT1, CEPT1, SLC18A2 | CYP3A4 1043/4885DYRK1A 2693/4885CYP11B2 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.